Pharmaceutical Headlines for 20 may 2011 ( Friday ) !
• AstraZeneca PLC (AZN) Chops Jobs in Massachusetts More...
• Takeda Pharmaceutical Co. Ltd. (TKDG.DE) Destroyed Shareholder Value More Than Any Drugmaker More...
• AstraZeneca PLC (AZN) Rumored to be Eyeing Up US Target, Analysts Believe Cubist Pharmaceuticals, Inc. (CBST) to be a Possibility More...
• Ridgemont Equity Takes Majority Stake In Gallus Biopharmaceuticals LLC More...
• Pfizer Inc. (PFE) Pays $7.5 Million Regulatory Milestone to Auxilium Pharmaceuticals (AUXL) More...
• Baylor College of Medicine and Golden Helix Collaborate to Put Better Rare Variant Analysis into the Hands of Researchers More...
• ASKA Pharmaceutical and HRA Pharma Announce Exclusive Licensing Agreement for Ulipristal Acetate to Treat Uterine Fibroids in Japan More...
• Titertek Instruments, Inc. and Berthold Technologies Have Joined Forces More...
• EMD Serono, Inc. (Rockland) President and CEO Fereydoun Firouz Resigns More...
• Shareholders OctoPlus Appoint Jan Egberts to Executive Board More...
• China Ruitai International Holdings Co., Ltd. Reports First Quarter 2011 Results More...
• Tibet Pharmaceuticals Announces Availability of First Quarter 2011 Earnings Call Transcript More...
• AstraZeneca PLC (AZN) Chops Jobs in Massachusetts More...
• Takeda Pharmaceutical Co. Ltd. (TKDG.DE) Destroyed Shareholder Value More Than Any Drugmaker More...
• AstraZeneca PLC (AZN) Rumored to be Eyeing Up US Target, Analysts Believe Cubist Pharmaceuticals, Inc. (CBST) to be a Possibility More...
• Ridgemont Equity Takes Majority Stake In Gallus Biopharmaceuticals LLC More...
• Pfizer Inc. (PFE) Pays $7.5 Million Regulatory Milestone to Auxilium Pharmaceuticals (AUXL) More...
• Baylor College of Medicine and Golden Helix Collaborate to Put Better Rare Variant Analysis into the Hands of Researchers More...
• ASKA Pharmaceutical and HRA Pharma Announce Exclusive Licensing Agreement for Ulipristal Acetate to Treat Uterine Fibroids in Japan More...
• Titertek Instruments, Inc. and Berthold Technologies Have Joined Forces More...
• EMD Serono, Inc. (Rockland) President and CEO Fereydoun Firouz Resigns More...
• Shareholders OctoPlus Appoint Jan Egberts to Executive Board More...
• China Ruitai International Holdings Co., Ltd. Reports First Quarter 2011 Results More...
• Tibet Pharmaceuticals Announces Availability of First Quarter 2011 Earnings Call Transcript More...
• FDA Approves Tibotec's HIV Drug Edurant More... • Pfizer Inc. (PFE): ELIQUIS(R) (apixaban) Approved In Europe For Preventing Venous Thromboembolism After Elective Hip Or Knee Replacement More... • American Regent, Inc. Initiates Nationwide Voluntary Recall of Sterile Water for Injection, USP, 50 mL Single Dose Vial Due to Particulate Matter More... • CHMP Issues Positive Opinion for Merck & Co., Inc. (MRK)'s VICTRELISTM (boceprevir), Oral Hepatitis C Virus (HCV) Protease Inhibitor More... • Amgen (AMGN) Receives CHMP Positive Opinion for XGEVA(TM) (Denosumab) in the European Union More... • Biogen Idec, Inc. (Massachusetts) (BIIB): European Medicines Agency's Committee for Medicinal Products for Human Use Issues Positive Opinion on Marketing Authorization Application for FAMPYRA More... • Acorda Therapeutics (ACOR) Statement on CHMP Positive Opinion on Marketing Authorization Application for FAMPYRA(R) in Europe More... • INSYS Therapeutics Announces NDA PDUFA Date for Fentanyl SL SprayMore... • FDA Panel Calls for New Trial on Abbott Laboratories (ABT)'s Trilipix More... • Progenics Pharmaceuticals, Inc. (PGNX) Announces Results of Methylnaltrexone Phase 3 Safety Study in Chronic, Non-Malignant Pain PatientsMore... • Onyx Pharmaceuticals, Inc. (ONXX) Announces Updated Pivotal Carfilzomib Phase 2B Data More... • Medivir AB (MVIRb.F) Announces Positive 48-week Interim Data from TMC435 Hepatitis C Phase 2b ASPIRE Study in Treatment-Experienced Genotype-1 Patients More... • Viagra Could Reduce Multiple Sclerosis Symptoms, Autonoma de Barcelona Study More... • Supplements 'Reduce Risk of Pre-Eclampsia' - Universidad Nacional Study More... • New Drug Targets for Squamous Cell Carcinoma, Fred Hutchinson Cancer Research Center Study More... • U.S. Navy Doctor's Drug Study Under Scrutiny More... • Study Finds 10% of Cancer Patients Abandon Oral Anti-Cancer Medications,Avalere Health Study Finds More... ( Source: Biospace ) |
0 comments